Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
4 hedge funds and large institutions have $116K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 6 → 4 (-2)
55% less capital invested
Capital invested by funds: $256K → $116K (-$140K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$39.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.1K |
| 3 |
CIA
Compass Ion Advisors
Conshohocken,
Pennsylvania
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $54K | -$39.6K | -145,968 | -35% |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| $26K | – | – | – |
|
|
PC
3
PointState Capital
New York
| $20K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $16K | -$14.1K | -51,981 | -40% |
|
|
CIA
5
Compass Ion Advisors
Conshohocken,
Pennsylvania
| – | -$4K | -10,000 | Closed |
|
OTLKW Hedge Fund Activity: Q3 2021 in Review
4 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q3 2021, worth a combined $116K — down 55% from $256K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of OTLKW and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Cormorant Asset Management, cutting an estimated $39.6K.
- 4 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q3 2021, down from 6 in Q2 2021.
- Funds reported $116K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q3 2021, down 55% quarter-over-quarter.
- 0 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q3 2021 and 2 closed out, a net change of -2 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q3 2021 was Cormorant Asset Management, an estimated $39.6K sold.
Based on aggregated 13F filings for Q3 2021.